Viral MIP-I Biotinylated Antibody Summary
Ala25-Ala95
Accession # NP_572066
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: MIP-I
Human herpesvirus-8 (HHV‑8)/Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus. HHV‑8 is etiologically linked to Kaposi’s sarcoma and a B-cell lymphoma known as primary effusion lymphoma. HHV‑8 has been shown to encode a variety of immunomodulatory proteins which were apparently pirated from cellular genes by the virus. Three chemokine-like proteins, vMIP-I, vMIP-II and vMIP-III have been found to be encoded within the HHV‑8 genome.
Viral MIP-I (also termed vMIP-1 alpha ) cDNA encodes a 95 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide that is cleaved to yield a 71 aa residue mature protein. Among human chemokines, vMIP-I is most closely related to MIP-1 alpha, sharing approximately 38% amino acid sequence identity. At the amino acid sequence level, vMIP-I and vMIP-II also share 48% identity. vMIP-I and vMIP-II are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. Both vMIP-I and vMIP-II have been shown to partially block HIV infection of peripheral blood mononuclear cells. vMIP-I and vMIP-II have also been found to be highly angiogenic in the chorioallantoic assay, suggesting that they may be partially responsible for the marked vascularity seen in KSHV-associated tumors.
Product Datasheets
Citation for Viral MIP-I Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth
Authors: Novobrantseva, T;Manfra, D;Ritter, J;Razlog, M;O'Nuallain, B;Zafari, M;Nowakowska, D;Basinski, S;Phennicie, RT;Nguyen, PA;Brehm, MA;Sazinsky, S;Feldman, I;
Cancers
Species: N/A
Sample Types: Antibody
Applications: ELISA Detection
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Viral MIP-I Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Viral MIP-I Biotinylated Antibody and earn rewards!
Have you used Viral MIP-I Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image